Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Status:
Withdrawn
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as
second-line chemotherapy in patients with advanced urothelial carcinoma.